JOHNSON & JOHNSON is 1.4x more valuable than AbbVie Inc. by market capitalization ($573.98 B vs $399.47 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | JNJ | ABBV |
|---|---|---|
| Market cap | $573.98 B | $399.47 B |
| US-listed rank | #20 | #28 |
| Revenue (latest FY) | $94.19B | $61.16B |
| Net income (latest FY) | $26.80B | $4.23B |
| Net margin | 28.5% | 6.9% |
| P/E (trailing FY) | 21.4 | 94.5 |
| SEC filings | 984 | 1,008 |
JOHNSON & JOHNSON is 1.4x more valuable than AbbVie Inc. by market capitalization ($573.98 B vs $399.47 B).
In their latest fiscal years, JOHNSON & JOHNSON reported $94.19B in revenue while AbbVie Inc. reported $61.16B.
Full pages: JOHNSON & JOHNSON and AbbVie Inc., or browse the full rankings.